ASTRAZENECA PLC-SPONS ADR (AZN) Stock News
NASDAQ:AZN - Nasdaq - US0463531089 - ADR - Currency: USD
AZN Latest News, Press Relases and Analysis
AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer
AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced that the FDA had granted accelerated approval to Datroway for the treatment of adult patients with non-small cell lung cancer (NSCLC). Datroway is the first and only TROP2-directed antibody-drug conjugate (ADC) approved […]
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.
Why Is Techne (TECH) Down 3% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: TECH
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Lennar Tops Revenue Estimates, Profit Falls Short as Discounts Fuel Home Sales
Shares of Lennar Corp. rose Tuesday morning, a day after the homebuilder posted a mixed second-quarter report, with revenue topping analysts' expectations but profit, new orders, and average sale price falling short.
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing […]
Berenberg Bank Maintains a Hold Rating on Novartis (NVS)
Novartis AG (NYSE:NVS) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. On June 12, Berenberg Bank analyst Luisa Hector maintained a Hold rating on Novartis AG (NYSE:NVS) and set a price target of CHF89.00. The same day, the company reported statistically significant improvements in the Phase IIIB APPULSE-PNH study. […]
Morgan Stanley Raises Tenet Healthcare (THC) PT to $210, Keeps Overweight Rating
Tenet Healthcare Corporation (NYSE:THC) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, Morgan Stanley raised its price target on Tenet Healthcare to $210 from $175, while maintaining an Overweight rating on the shares. Analyst Craig Hettenbach highlighted Tenet Healthcare as Morgan Stanley’s preferred stock within the hospital sector. […]
Morgan Stanley Initiates Centene (CNC) with Overweight Rating, Sets $70 PT
Centene Corporation (NYSE:CNC) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, Morgan Stanley initiated coverage on Centene with an Overweight rating and a price target of $70. Analyst Ricky Goldwasser noted that while varying permutations of policy headwinds are looming across Medicaid, this potential negative impact is disproportionately […]
Truist Lowers Elevance Health (ELV) to $500, Keeps Buy Rating
Elevance Health Inc. (NYSE:ELV) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, Truist analyst David MacDonald slightly reduced the firm’s price target on Elevance Health from $510 to $500, while maintaining a Buy rating on the shares. Despite the adjustment, the analyst remains positive on Elevance Health’s substantial […]
Spectris rejects second KKR proposal in favour of Advent's $5 billion bid
Spectris did not provide details on KKR's proposal, noting only that it was the second proposal by the private equity firm it had rejected. The company, which provides hardware and software solutions to sectors such as pharmaceuticals, steel and automotive, said on Monday it would accept private equity firm Advent's proposal of 37.63 pounds per share, if a formal offer was made.
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca continues Western big pharma’s growing dependence on Chinese biotechs for drug discovery.
AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer
CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.
J.C. Flowers-backed Jefferson Capital eyes $1.1 billion valuation in US IPO
(Reuters) -Private equity-backed Jefferson Capital said on Friday it was targeting a valuation of up to $1.1 billion in its U.S. initial public offering, as buyout firms look to take advantage of an improving new listings market. Jefferson and some existing investors are seeking to raise up to $170 million by offering 10 million shares priced between $15 and $17 each, in what would be a rare flotation from the debt buyer industry. Mounting pressure to return money to investors is encouraging buyout firms to list their portfolio companies.
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock surge and Third Harmonic kicked off a drug auction.
Want Exposure to Nvidia, Microsoft, and Tesla? This New ETF Covers Them All.
Wedbush tech analyst Dan Ives oversees the ETF that bears his name. Exchange-traded funds (ETFs) are a great way to gain exposure to the hot field of artificial intelligence (AI). A new AI ETF emerged recently, and what makes this one stand out is that it's overseen by Dan Ives, the global head of technology research at Wall Street firm Wedbush Fund Advisors.
AstraZeneca signs AI research deal with China's CSPC for chronic diseases
The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases, with CSPC conducting AI-driven research in Shijiazhuang City.
Citi Opens Positive Catalyst Watch on Microsoft (MSFT), Sees $605 Price Target on Strong Azure Outlook
Microsoft Corporation (NASDAQ:MSFT) is one of the 15 AI Stocks Making Waves on Wall Street. On June 11, Citi opened a positive catalyst watch on Microsoft. The firm said estimates for the company’s Azure are too low. Its analyst, Tyler Radke, reiterated a “Buy” rating on the stock with a $605.00 price target. “We open […]
Insmed (INSM) Soars After Raising $650 million
We recently published a list of These 10 Stocks Are Flying High. In this article, we are going to take a look at where Insmed Inc. (NASDAQ:INSM) stands against other best-performing stocks on Wednesday. Insmed jumped for a second day on Wednesday, adding 7.75 percent to close at $97.98 apiece following plans to raise $650 […]
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
IonQ just hit investors with two pieces of big news. One shows proof of the company's tech being useful near-term. The other looks to aid its long-term goals.
Amazon Ups Its AI Infrastructure Ante
The cloud giant is continuing to build out its massive cloud footprint.
Is D-Wave Quantum a Better Quantum Computing Stock to Buy Than IonQ?
Palantir CEO Warns US-China AI Race Will Have One Winner, Urges West To Keep Up
Palantir Technologies Inc (NASDAQ:PLTR) CEO Alex Karp expects the artificial intelligence arms race between the U.S. and China to have one winner. Karp, on Thursday’s episode of CNBC’s “Squawk on the Street,” expressed his concerns regarding AI’s ...
Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success
Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with Regeneron Pharmaceuticals, marking a significant advance in COPD treatment. This decline comes in contrast to a 2% rise in the broader market, suggesting that investors may be focusing on other company initiatives, such as SNY’s recent […]
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
US stocks edge toward records with inflation data, policy progress in focus
NEW YORK (Reuters) -The U.S. stock rebound has driven key indexes to the cusp of record levels, with fresh economic data and trade and fiscal policy developments set to test whether equities will get an extra push higher in the near term. Equities have bounced back from a steep fall in April, sparked by concerns about the economic fallout from President Donald Trump's tariff plans. "I'd still say it's a cautious tone" in the market, said Jim Baird, chief investment officer with Plante Moran Financial Advisors.